NCT07187063Recruiting
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 15 Aug 2025
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Jan 2029
- Lead sponsor
- Lahey Clinic
- Diseases
- Bladder cancer
- NCT number
- NCT07187063
What you commit to
- Study type: Interventional
- Planned participants: 56
- From 1 Jan 2025 to the primary completion date, 1 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior induction intravesical therapy
- Concurrent upper tract disease
Other
- High-risk NMIBC within 3 years
- Variant histology
Who the study is looking for
- AUA high-risk bladder cancer1
- Received induction BCG or gemcitabine/docetaxel
- Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lahey Hospital and Medical Center Coordinator of this site? Confirm its status | Burlington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.